Related references
Note: Only part of the references are listed.The 2016 WHO Classification of Tumours of the Urinary System and Male Genital Organs-Part A: Renal, Penile, and Testicular Tumours
Holger Moch et al.
EUROPEAN UROLOGY (2016)
A Clearer View of the Molecular Complexity of Clear Cell Renal Cell Carcinoma
Ian J. Frew et al.
ANNUAL REVIEW OF PATHOLOGY: MECHANISMS OF DISEASE, VOL 10 (2015)
Analyses of Potential Predictive Markers and Response to Targeted Therapy in Patients with Advanced Clear-cell Renal Cell Carcinoma
Yan Song et al.
CHINESE MEDICAL JOURNAL (2015)
Molecular Subtypes of Clear Cell Renal Cell Carcinoma Are Associated with Sunitinib Response in the Metastatic Setting
Benoit Beuselinck et al.
CLINICAL CANCER RESEARCH (2015)
International Variations and Trends in Renal Cell Carcinoma Incidence and Mortality
Ariana Znaor et al.
EUROPEAN UROLOGY (2015)
BAP1, PBRM1 and SETD2 in clear-cell renal cell carcinoma: molecular diagnostics and possible targets for personalized therapies
Francesco Piva et al.
EXPERT REVIEW OF MOLECULAR DIAGNOSTICS (2015)
The roles of chromatin-remodelers and epigenetic modifiers in kidney cancer
Lili Liao et al.
CANCER GENETICS (2015)
VHL, the story of a tumour suppressor gene
Lucy Gossage et al.
NATURE REVIEWS CANCER (2015)
Clinical and pathological impact of VHL, PBRM1, BAP1, SETD2, KDM6A, and JARID1c in clear cell renal cell carcinoma
Lucy Gossage et al.
GENES CHROMOSOMES & CANCER (2014)
An integrated computational approach can classify VHL missense mutations according to risk of clear cell renal carcinoma
Lucy Gossage et al.
HUMAN MOLECULAR GENETICS (2014)
Molecular Genetics of Clear-Cell Renal Cell Carcinoma
James Brugarolas
JOURNAL OF CLINICAL ONCOLOGY (2014)
Genomic architecture and evolution of clear cell renal cell carcinomas defined by multiregion sequencing
Marco Gerlinger et al.
NATURE GENETICS (2014)
Mutational status of VHL gene and its clinical importance in renal clear cell carcinoma
Mariana Rezende Alves et al.
VIRCHOWS ARCHIV (2014)
PBRM1 and BAP1 as Novel Targets for Renal Cell Carcinoma
James Brugarolas
CANCER JOURNAL (2013)
Adverse Outcomes in Clear Cell Renal Cell Carcinoma with Mutations of 3p21 Epigenetic Regulators BAP1 and SETD2: A Report by MSKCC and the KIRC TCGA Research Network
A. Ari Hakimi et al.
CLINICAL CANCER RESEARCH (2013)
Aberrant promoter hypermethylation of PBRM1, BAP1, SETD2, KDM6A and other chromatin-modifying genes is absent or rare in clear cell RCC
Ilsiya Ibragimova et al.
EPIGENETICS (2013)
Pleiotropic Effects of the Trichloroethylene-Associated P81S VHL Mutation on Metabolism, Apoptosis, and ATM-Mediated DNA Damage Response
Michelle C. DeSimone et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2013)
Effects on survival of BAP1 and PBRM1 mutations in sporadic clear-cell renal-cell carcinoma: a retrospective analysis with independent validation
Payal Kapur et al.
LANCET ONCOLOGY (2013)
Comprehensivemolecular characterization of clear cell renal cell carcinoma
Chad J. Creighton et al.
NATURE (2013)
The VHL/HIF axis in clear cell renal carcinoma
Chuan Shen et al.
SEMINARS IN CANCER BIOLOGY (2013)
Proteostasis Modulators Prolong Missense VHL Protein Activity and Halt Tumor Progression
Chunzhang Yang et al.
CELL REPORTS (2013)
The interaction of the von Hippel-Lindau tumor suppressor and heterochromatin protein 1
Yanlai Lai et al.
ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS (2012)
JunB promotes cell invasion and angiogenesis in VHL-defective renal cell carcinoma
T. Kanno et al.
ONCOGENE (2012)
Whole genome and transcriptome amplification: practicable tools for sustainable tissue biobanking?
Adriana von Teichman et al.
VIRCHOWS ARCHIV (2012)
Reliable detection of subclonal single-nucleotide variants in tumour cell populations
Moritz Gerstung et al.
NATURE COMMUNICATIONS (2012)
VHL Gene Mutations and Their Effects on Hypoxia Inducible Factor HIFα: Identification of Potential Driver and Passenger Mutations
Markus P. Rechsteiner et al.
CANCER RESEARCH (2011)
von Hippel-Lindau-Dependent Patterns of RNA Polymerase II Hydroxylation in Human Renal Clear Cell Carcinomas
Ying Yi et al.
CLINICAL CANCER RESEARCH (2010)
Alterations in VHL as potential biomarkers in renal-cell carcinoma
Lucy Gossage et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2010)
The genetic basis of kidney cancer: a metabolic disease
W. Marston Linehan et al.
NATURE REVIEWS UROLOGY (2010)
Analysis of VHL Gene Alterations and their Relationship to Clinical Parameters in Sporadic Conventional Renal Cell Carcinoma
Alison C. Young et al.
CLINICAL CANCER RESEARCH (2009)
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
E. A. Eisenhauer et al.
EUROPEAN JOURNAL OF CANCER (2009)
Adding structural information to the von Hippel-Lindau (VHL) tumor suppressor interaction network
E. Leonardi et al.
FEBS LETTERS (2009)
VHL Gene Mutations in Renal Cell Carcinoma: Role as a Biomarker of Disease Outcome and Drug Efficacy
C. Lance Cowey et al.
CURRENT ONCOLOGY REPORTS (2009)
Improved identification of von Hippel-Lindau gene alterations in clear cell renal tumors
Michael L. Nickerson et al.
CLINICAL CANCER RESEARCH (2008)
eEF1A Is a Novel Component of the Mammalian Nuclear Protein Export Machinery
Mireille Khacho et al.
MOLECULAR BIOLOGY OF THE CELL (2008)
PVHL co-ordinately regulates CXCR4/CXCL12 and MMP2/MMP9 expression in human clear-cell renal cell carcinoma
K. Struckmann et al.
JOURNAL OF PATHOLOGY (2008)
Somatic von Hippel-Lindau (VHL) gene analysis and clinical outcome under antiangiogenic treatment in metastatic renal cell carcinoma: preliminary results
Sophie Gad et al.
TARGETED ONCOLOGY (2007)
Genetic and epigenetic analysis of von Hippel-Lindau (VHL) gene alterations and relationship with clinical variables in sporadic renal cancer
RE Banks et al.
CANCER RESEARCH (2006)
Neuronal apoptosis linked to EgIN3 prolyl hydroxylase and familial pheochromocytoma genes: Developmental culling and cancer
S Lee et al.
CANCER CELL (2005)
Tumor suppressor von Hippel-Lindau (VHL) stabilization of Jade-1 protein occurs through plant homeodomains and is VHL mutation dependent
MI Zhou et al.
CANCER RESEARCH (2004)
The von Hippel-Lindau tumor suppressor gene and kidney cancer
WG Kaelin
CLINICAL CANCER RESEARCH (2004)
Tumorigenic mutations in VHL disrupt folding in vivo by interfering with chaperonin binding
DE Feldman et al.
MOLECULAR CELL (2003)
Relevance of nuclear and cytoplasmic von Hippel Lindau protein expression for renal carcinoma progression
P Schraml et al.
AMERICAN JOURNAL OF PATHOLOGY (2003)
Comprehensive mutational analysis of the VHL gene in sporadic renal cell carcinoma:: Relationship to clinicopathological parameters
K Kondo et al.
GENES CHROMOSOMES & CANCER (2002)
Ubiquitination of a novel deubiquitinating enzyme requires direct binding to von Hippel-Lindau tumor suppressor protein
ZB Li et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2002)
VHL mutations and their correlation with tumour cell proliferation, microvessel density, and patient prognosis in clear cell renal cell carcinoma
P Schraml et al.
JOURNAL OF PATHOLOGY (2002)
von Hippel-Lindau protein mutants linked to type 2C VHL disease preserve the ability to downregulate HIF
MA Hoffman et al.
HUMAN MOLECULAR GENETICS (2001)
Share Paper
